Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Expenses (2016 - 2026)

Agios Pharmaceuticals filings provide 15 years of Operating Expenses readings, the most recent being $130.8 million for Q1 2026.

  • On a quarterly basis, Operating Expenses rose 13.36% to $130.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $541.6 million, a 13.46% increase, with the full-year FY2025 number at $526.2 million, up 13.83% from a year prior.
  • Operating Expenses hit $130.8 million in Q1 2026 for Agios Pharmaceuticals, down from $141.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $141.5 million in Q4 2025 to a low of $94.6 million in Q3 2022.
  • Median Operating Expenses over the past 5 years was $111.8 million (2024), compared with a mean of $114.2 million.
  • Biggest five-year swings in Operating Expenses: dropped 5.64% in 2023 and later grew 21.92% in 2025.
  • Agios Pharmaceuticals' Operating Expenses stood at $103.5 million in 2022, then increased by 9.56% to $113.4 million in 2023, then grew by 19.75% to $135.8 million in 2024, then grew by 4.26% to $141.5 million in 2025, then fell by 7.61% to $130.8 million in 2026.
  • The last three reported values for Operating Expenses were $130.8 million (Q1 2026), $141.5 million (Q4 2025), and $129.7 million (Q3 2025) per Business Quant data.